Hemostemix Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Public

  • Employees
  • 13

Employees

  • Stock Symbol
  • HEM

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.02
  • (As of Wednesday Closing)

Hemostemix General Information

Description

Hemostemix Inc is a clinical-stage biotechnology company whose principal business is to develop, manufacture, and commercialize blood-derived stem cell therapies for medical conditions not adequately addressed by current treatments. Its product ACP-01 is derived from a patient's own blood and evaluated in clinical research for ischemic conditions, including Cardiovascular Ischemia, Peripheral Arterial Disease (PAD), Chronic Limb Threatening Ischemia (CLTI), and Vascular Dementia.

Contact Information

Formerly Known As
TheraVitae, Technical Ventures RX
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 707 Seventh Avenue South West
  • Suite 1150
  • Calgary, Alberta T2P 3H6
  • Canada
+1 (905)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
TSX
Corporate Office
  • 707 Seventh Avenue South West
  • Suite 1150
  • Calgary, Alberta T2P 3H6
  • Canada
+1 (905)

Hemostemix Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hemostemix Stock Performance

As of 18-Nov-2026, Hemostemix’s stock price is $0.02. Its current market cap is $5.17M with 211M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.02 $0.02 $0.02 - $0.08 $5.17M 211M 57.7K -$0.02

Hemostemix Financials Summary

As of 30-Jun-2026, Hemostemix has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 10,253 13,950 15,042 7,566
Revenue 0 0 0 0
EBITDA (3,115) (3,047) (1,459) (1,445)
Net Income (3,286) (3,371) (1,908) (1,853)
Total Assets 181 618 691 237
Total Debt 2,508 2,630 3,440 3,258
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Hemostemix Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Hemostemix‘s full profile, request access.

Request a free trial

Hemostemix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hemostemix Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Hemostemix‘s full profile, request access.

Request a free trial

Hemostemix Acquisitions (2)

Hemostemix’s most recent deal was a Merger/Acquisition with Hemostemix (Two Cardiology Practices). The deal was made on 03-Dec-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Hemostemix (Two Cardiology Practices) 03-Dec-2025 Merger/Acquisition Other Healthcare Services
Technical Ventures RX 12-Nov-2014 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view Hemostemix’s complete acquisitions history, request access »

Hemostemix ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Hemostemix’s complete esg history, request access »

Hemostemix FAQs

  • When was Hemostemix founded?

    Hemostemix was founded in 2003.

  • Where is Hemostemix headquartered?

    Hemostemix is headquartered in Calgary, Canada.

  • What is the size of Hemostemix?

    Hemostemix has 13 total employees.

  • What industry is Hemostemix in?

    Hemostemix’s primary industry is Biotechnology.

  • Is Hemostemix a private or public company?

    Hemostemix is a Public company.

  • What is Hemostemix’s stock symbol?

    The ticker symbol for Hemostemix is HEM.

  • What is the current stock price of Hemostemix?

    As of 18-Nov-2026 the stock price of Hemostemix is $0.02.

  • What is the current market cap of Hemostemix?

    The current market capitalization of Hemostemix is $5.17M.

  • What is Hemostemix’s annual earnings per share (EPS)?

    Hemostemix’s EPS for 12 months was -$0.02.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process